330 related articles for article (PubMed ID: 16217291)
1. Androgen deprivation use with external beam radiation for prostate cancer: results from CaPSURE.
Park S; Meng MV; Elkin EP; Speight JL; DuChane J; Carroll PR
J Urol; 2005 Nov; 174(5):1802-7. PubMed ID: 16217291
[TBL] [Abstract][Full Text] [Related]
2. Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): an open-label, randomised, phase 3 factorial trial.
Denham JW; Joseph D; Lamb DS; Spry NA; Duchesne G; Matthews J; Atkinson C; Tai KH; Christie D; Kenny L; Turner S; Gogna NK; Diamond T; Delahunt B; Oldmeadow C; Attia J; Steigler A
Lancet Oncol; 2014 Sep; 15(10):1076-89. PubMed ID: 25130995
[TBL] [Abstract][Full Text] [Related]
3. High-dose radiation employing external beam radiotherapy and high-dose rate brachytherapy with and without neoadjuvant androgen deprivation for prostate cancer patients with intermediate- and high-risk features.
Vargas C; Martínez A; Galalae R; Demanes J; Harsolia A; Schour L; Nuernberg N; Gonzalez J
Prostate Cancer Prostatic Dis; 2006; 9(3):245-53. PubMed ID: 16786040
[TBL] [Abstract][Full Text] [Related]
4. Risk-adapted androgen deprivation and escalated three-dimensional conformal radiotherapy for prostate cancer: Does radiation dose influence outcome of patients treated with adjuvant androgen deprivation? A GICOR study.
Zapatero A; Valcárcel F; Calvo FA; Algás R; Béjar A; Maldonado J; Villá S
J Clin Oncol; 2005 Sep; 23(27):6561-8. PubMed ID: 16170164
[TBL] [Abstract][Full Text] [Related]
5. Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE).
Kawakami J; Cowan JE; Elkin EP; Latini DM; DuChane J; Carroll PR;
Cancer; 2006 Apr; 106(8):1708-14. PubMed ID: 16544313
[TBL] [Abstract][Full Text] [Related]
6. No apparent benefit at 5 years from a course of neoadjuvant/concurrent androgen deprivation for patients with prostate cancer treated with a high total radiation dose.
Martinez A; Galalae R; Gonzalez J; Mitchell C; Gustafson G; Kovacs G
J Urol; 2003 Dec; 170(6 Pt 1):2296-301. PubMed ID: 14634400
[TBL] [Abstract][Full Text] [Related]
7. Excellent results from high dose rate brachytherapy and external beam for prostate cancer are not improved by androgen deprivation.
Demanes DJ; Brandt D; Schour L; Hill DR
Am J Clin Oncol; 2009 Aug; 32(4):342-7. PubMed ID: 19398902
[TBL] [Abstract][Full Text] [Related]
8. High-dose radiotherapy with short-term or long-term androgen deprivation in localised prostate cancer (DART01/05 GICOR): a randomised, controlled, phase 3 trial.
Zapatero A; Guerrero A; Maldonado X; Alvarez A; Gonzalez San Segundo C; Cabeza Rodríguez MA; Macias V; Pedro Olive A; Casas F; Boladeras A; de Vidales CM; Vazquez de la Torre ML; Villà S; Perez de la Haza A; Calvo FA
Lancet Oncol; 2015 Mar; 16(3):320-7. PubMed ID: 25702876
[TBL] [Abstract][Full Text] [Related]
9. National practice patterns and time trends in androgen ablation for localized prostate cancer.
Cooperberg MR; Grossfeld GD; Lubeck DP; Carroll PR
J Natl Cancer Inst; 2003 Jul; 95(13):981-9. PubMed ID: 12837834
[TBL] [Abstract][Full Text] [Related]
10. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer.
D'Amico AV; Whittington R; Malkowicz SB; Schultz D; Blank K; Broderick GA; Tomaszewski JE; Renshaw AA; Kaplan I; Beard CJ; Wein A
JAMA; 1998 Sep; 280(11):969-74. PubMed ID: 9749478
[TBL] [Abstract][Full Text] [Related]
11. Lack of benefit from a short course of androgen deprivation for unfavorable prostate cancer patients treated with an accelerated hypofractionated regime.
Martinez AA; Demanes DJ; Galalae R; Vargas C; Bertermann H; Rodriguez R; Gustafson G; Altieri G; Gonzalez J
Int J Radiat Oncol Biol Phys; 2005 Aug; 62(5):1322-31. PubMed ID: 16029788
[TBL] [Abstract][Full Text] [Related]
12. Survival Among Men at High Risk of Disseminated Prostate Cancer Receiving Initial Locally Directed Radical Treatment or Initial Androgen Deprivation Therapy.
Sooriakumaran P; Nyberg T; Akre O; Widmark A; Hamdy F; Graefen M; Carlsson S; Steineck G; Wiklund NP
Eur Urol; 2017 Sep; 72(3):345-351. PubMed ID: 28416350
[TBL] [Abstract][Full Text] [Related]
13. Usefulness of J-CAPRA score for high-risk prostate cancer patients treated with carbon ion radiotherapy plus androgen deprivation therapy.
Akakura K; Tsuji H; Suzuki H; Ichikawa T; Ishikawa H; Okada T; Kamada T; Harada M; Tsujii H; Shimazaki J
Jpn J Clin Oncol; 2014 Apr; 44(4):360-5. PubMed ID: 24585931
[TBL] [Abstract][Full Text] [Related]
14. Short-term androgen-deprivation therapy improves prostate cancer-specific mortality in intermediate-risk prostate cancer patients undergoing dose-escalated external beam radiation therapy.
Zumsteg ZS; Spratt DE; Pei X; Yamada Y; Kalikstein A; Kuk D; Zhang Z; Zelefsky MJ
Int J Radiat Oncol Biol Phys; 2013 Mar; 85(4):1012-7. PubMed ID: 22981709
[TBL] [Abstract][Full Text] [Related]
15. Does prostate-specific antigen nadir predict longer-term outcomes of prostate cancer after neoadjuvant and adjuvant androgen deprivation therapy in conjunction with brachytherapy?
Morris LM; Izard MA; Wan WY
Brachytherapy; 2015; 14(3):322-8. PubMed ID: 25487524
[TBL] [Abstract][Full Text] [Related]
16. High-intermediate prostate cancer treated with low-dose-rate brachytherapy with or without androgen deprivation therapy.
Pickles T; Morris WJ; Keyes M
Brachytherapy; 2017; 16(6):1101-1105. PubMed ID: 29032014
[TBL] [Abstract][Full Text] [Related]
17. Dose escalation with three-dimensional conformal radiotherapy for prostate cancer. Is more dose really better in high-risk patients treated with androgen deprivation?
Zapatero A; Ríos P; Marín A; Mínguez R; García-Vicente F
Clin Oncol (R Coll Radiol); 2006 Oct; 18(8):600-7. PubMed ID: 17051950
[TBL] [Abstract][Full Text] [Related]
18. Outcomes and toxicities in patients with intermediate-risk prostate cancer treated with brachytherapy alone or brachytherapy and supplemental external beam radiation therapy.
Schlussel Markovic E; Buckstein M; Stone NN; Stock RG
BJU Int; 2018 May; 121(5):774-780. PubMed ID: 29319919
[TBL] [Abstract][Full Text] [Related]
19. Evolution of definitive external beam radiation therapy in the treatment of prostate cancer.
Daly T
World J Urol; 2020 Mar; 38(3):565-591. PubMed ID: 30850855
[TBL] [Abstract][Full Text] [Related]
20. External Beam Radiation Therapy or Brachytherapy With or Without Short-course Neoadjuvant Androgen Deprivation Therapy: Results of a Multicenter, Prospective Study of Quality of Life.
Gay HA; Sanda MG; Liu J; Wu N; Hamstra DA; Wei JT; Dunn RL; Klein EA; Sandler HM; Saigal CS; Litwin MS; Kuban DA; Hembroff L; Regan MM; Chang P; ; Michalski JM
Int J Radiat Oncol Biol Phys; 2017 Jun; 98(2):304-317. PubMed ID: 28463150
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
